A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CROSSOVER STUDY OF SAGE-718 USING A KETAMINE CHALLENGE, TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMIC RESPONSE USING MAGNETIC RESONANCE IMAGING IN HEALTHY SUBJECTS
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Jan 2019
At a glance
- Drugs SAGE 718
- Indications Smith-Lemli-Opitz syndrome
- Focus Pharmacodynamics
- 07 Jan 2019 According to a media release, topline results from this study is anticipated in 1H 2019.
- 07 Dec 2018 Status changed from planning to not yet recruiting.
- 07 Aug 2018 According to a Sage Therapeutics media release, top-line results from the study are expected in 4Q 2018.